Faecal Microbiota Transplantation and Obesity
Faecal microbiota transplantation transfers stool from a screened healthy donor into the gut; in obesity it can shift the gut bacteria and slightly improve glucose markers, but trials have not produced weight loss.
Plain English
Patient-Friendly Explanation
Faecal microbiota transplantation, usually shortened to FMT, means transferring stool from a healthy screened donor into another person's gut, either as a liquid through a tube or endoscope, or as swallowed capsules of frozen prepared material. It is an established and effective treatment for repeated Clostridioides difficile infection, where it restores a normal gut bacterial community and can be life-changing. The interest in weight came from animal experiments. When gut bacteria from obese mice or from people with obesity were transferred into mice without gut bacteria of their own, the animals gained more fat, which suggested that the gut community could influence body weight. Human results have been much more modest. Small studies from the Netherlands found that infusing stool from lean donors into men with obesity and metabolic syndrome improved insulin sensitivity, by a large margin in the first small study and by a smaller amount in the follow-up, but the improvement disappeared within twelve to eighteen weeks as the gut bacteria returned to their previous state. A later randomised trial of weekly capsules in twenty-four adults with obesity found that the treatment did change the gut bacteria in most participants and was well tolerated, but there was no significant improvement in insulin sensitivity, no change in body weight and no change in body composition. A pooled analysis of nine randomised trials including about three hundred people found small improvements in fasting glucose, glycated haemoglobin, insulin and HDL cholesterol in the short term, but no significant weight reduction. Safety deserves a clear statement. In the trials the treatment was generally well tolerated, but transferring stool carries a genuine risk of passing on infection if donors are not properly screened, and serious infections have been reported. FMT is not an approved treatment for obesity anywhere, and it should not be offered or bought as a weight-loss procedure. For now it remains a research area, while the interventions with proven effect on body weight remain diet, physical activity, behavioural support and, where appropriate, medication and surgery.
Medical
Clinical Definition
Faecal microbiota transplantation is the administration of processed stool from a screened healthy donor, by nasogastric or nasoduodenal tube, colonoscopy, enema or oral capsule, to restore the intestinal microbiota; its established indication is recurrent Clostridioides difficile infection. Interest in obesity arose from experiments in mice raised without any gut bacteria, in which transfer of microbiota from obese donors conferred greater fat gain than transfer from lean donors. Human data are limited and inconsistent. In a pilot study, nine men with metabolic syndrome who received allogenic lean-donor infusion showed a substantial improvement in peripheral insulin sensitivity at six weeks (median insulin-mediated glucose uptake approximately 73% higher than baseline) with increased microbial diversity; a larger follow-up study (26 recipients) showed a more modest improvement (about 12%) and a small fall in HbA1c, with the metabolic and microbial changes reverting by 12-18 weeks. In the FMT-TRIM double-blind randomised placebo-controlled pilot trial, 24 adults with obesity and mild to moderate insulin resistance (HOMA-IR 2.0 to 8.0) received weekly oral donor FMT or placebo capsules for six weeks: insulin-stimulated glucose uptake changed by +5% in the FMT group versus -3% with placebo (mean difference 9%, 95% CI -5% to 28%, p=0.16), with no significant change in body weight, body composition, HOMA-IR, fasting lipids or resting energy expenditure over 12 weeks, despite durable engraftment of donor bacterial groups in most participants and no serious adverse events. A meta-analysis of nine randomised controlled trials including 303 participants found that FMT lowered fasting glucose, HbA1c and insulin and raised HDL cholesterol at less than six weeks, but did not produce significant weight reduction; the authors rated the quality of evidence low. Autologous FMT (reinfusion of a participant's own stool collected at the weight-loss nadir) has shown attenuation of weight regain in an exploratory randomised trial, an effect associated with changes in low-abundance gut species, but this is early work and is not a clinical treatment. Donor screening is essential and transmission of multi-drug-resistant organisms and other pathogens has been reported; FMT remains unapproved for obesity and is not indicated as a weight-loss intervention.
Key Insight
Why It Matters
Patients ask about faecal transplantation because media coverage often describes the gut microbiome as a cause of obesity, and some private clinics market stool-derived treatments for weight loss. The honest position is that changing the gut bacteria alone has not produced weight loss in randomised trials, and that the procedure carries infection risk. Its place is in treating recurrent Clostridioides difficile infection, not obesity. Where the gut microbiome does help patients is through diet: fibre, resistant starch and fermented foods shape the bacterial community in a way that supports metabolic health, at no risk and no cost.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: October 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
